One Design Company’s Post

𝗧𝗵𝗲 𝗰𝗹𝗮𝘀𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗯𝗲𝘀𝘁 𝗶𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 - 𝗧𝗼𝗽 𝟭𝟱! 🔥 Biotech is a highly saturated to say the least with so many coming and going within such a short period of time. This makes it very difficult to have an in depth view of who is leading the discovery curve for new therapeutics with such bold claims presented weekly. However, luckily we have our friends over at Fierce Biotech who have done the ground work for us! Check out the link below on this super exciting read on who to keep an eye on! 𝗛𝗮𝘃𝗲 𝗮 𝗹𝗼𝗼𝗸 𝘆𝗼𝘂𝗿𝘀𝗲𝗹𝗳 𝗮𝗻𝗱 𝗹𝗲𝘁 𝗺𝗲 𝗸𝗻𝗼𝘄 𝘄𝗵𝗼 𝘆𝗼𝘂 𝘄𝗼𝘂𝗹𝗱 𝗵𝗮𝘃𝗲 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗮𝗻𝗱 𝘁𝗮𝗴 𝘁𝗵𝗲𝗺 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁 𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝗯𝗲𝗹𝗼𝘄 Companies included are: Abdera Therapeutics Ascidian Therapeutics BigHat Biosciences Cour Pharmaceuticals Development Co., Inc. Excision BioTherapeutics Fauna Bio Gilgamesh Pharmaceuticals iECURE, inc. ILiAD Biotechnologies, LLC Kimer Med NodThera OMass Therapeutics ProFound Therapeutics Recludix Pharma Tubulis GmbH #Biotech #Therapeutics #BiotechNews https://lnkd.in/eX3g_wgP

Read the blog: https://ow.ly/CQpx50Sw2Ww Check out the latest AMCP Dossier Format Version 5.0. Learn about health disparities, real-world evidence, digital therapeutics, and more. Authors: Joshua Gauci, Irene Zahirovic (Zelner), PhD, Deepika Thakur #AMCP #HealthDisparities #RWE #DigitalTheraeutics

📰 #SharingThursday "There are ~7,000 rare diseases that together affect 300 million people. For the vast majority of these patients there are no approved treatments, representing a huge unmet medical need". A new article from our president James Levine and our colleague Clea Stemitsiotis published in Nature Reviews and completely free for one week! "De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors" 🤝 Read it now 👇 https://lnkd.in/gze9Jd4g #raredisease #medicalresearch #sciences #derisking #biotech

The mapping table of DTx (digital therapeutics) products, their targeted conditions, and related patent owners provides a comprehensive overview of the current landscape and potential developments in DTx for various health conditions. This mapping highlights the diversity and specialization in the DTx field, illustrating the range of conditions being targeted and the innovation in their respective therapeutic approaches. This table is based on the global DTx patent analysis as of 1Q 2024. Some of the key patent owners are: Dthera Sciences, S-Alpha Therapeutics, Altoida, Inc., CogMe, Cognito Therapeutics, Inc., MapHabit, SocialDream, Wohlfahrtsstiftung der F. Hoffmann-La Roche AG, Beats Medical, MedRhythms, Inc., MindMaze, Ki Health Concepts - Kinect Health, Freespira, NightWare, Twill, Woebot Health, RealizedCare, Click Therapeutics, Inc., HeadSpace Mental Health, PLLC, Ellipsis Health, Oui Therapeutics, BeMe Health, Neumora, Reulay Inc, atai Life Sciences, Big Health, Propeller Health, Elekta Kaiku, Blue Note Therapeutics, NihayTech.ai, Welldoc, Hygieia, Virta Health, Theranica, WELT corp, Swing Therapeutics, Inc., CureApp, Inc., BioBeats (a Huma company), Pivot Health Group #digitalhealth #digitaltherapeutics #product #innovation #patent

👏🏼👏🏼👏🏼 A big shoutout to Jordan Shlain, MD and Ken Rutkowski for sharing the latest and greatest in longevity medicine! Thank you 🙏🏼 for keeping us informed with non BS peer-reviewed therapies and therapeutics. If you're not already following Jordan, make sure to do so for expert insights and cutting-edge information. #LongevityMedicine #ExpertInsights #PeerReviewedTherapies

PharmaVoice breaks down the potentially seismic impacts of CRISPR-based therapies, with data from Norstella companies Citeline and Evaluate Ltd and commentary from Jen (Goldenberg) Klarer of The Dedham Group, where Jen underscores the promise and complexity of these treatments. Read the article here: https://ow.ly/pybG50QjgaM. #Pipeline2Patient #Norstella

I would love to see more people improve their health with this. Matomo.myalovea.com Acemannan is being integrated into high levels of medical research! Dr. Renee Hirte has been supervising the research of the plant extract, Acemannan, and says it has exceeded expectations. The goal of this research project is to validate the integrative support it can provide our monoclonal antibody therapy to achieve the best patient outcomes. Additionally, Ron Bruno, Board Director of Netwell Healthshare, says that "Alovéa’s proprietary Acemannan product IMMUN, is the most scientifically-validated technology we were able to find for achieving [our] goals." Acemannan is revolutionizing health, and we're lucky enough to share its benefits with the world. #dailyhealthyhabits #optimizeyourhealth #autoimmunesupport

From research to realization, the process for advanced therapeutic modalities (ATMs) is radically different — so much so that it fundamentally shifts R&D timelines, challenges, and sources of risk.

The Life Sciences industry is shifting. Have you considered the impact of innovations, and your processes to develop strategies to participate in the next wave of change.